Navigation Links
Sensipar® Patents Upheld By District Court
Date:1/7/2011

THOUSAND OAKS, Calif., Jan. 7, 2011 /PRNewswire/ -- A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's (Nasdaq: AMGN) Sensipar® (cinacalcet) until expiration of the drug's U.S. patents.  The latest Sensipar expiry is in 2018.  Sensipar is approved for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis and for the treatment of elevated levels of calcium in patients with parathyroid carcinoma.

"We are pleased with the Court's ruling, which validates Amgen's position that the Sensipar patents are valid, enforceable and infringed," said David Scott, Amgen's senior vice president, general counsel and secretary. Scott added: "Amgen will continue to vigorously defend its innovative products from infringement."

Three patents were the subject of the injunction: U.S. Patent No. 6,011,068 ("the `068 patent") and U.S. Patent No. 6,031,003 expire Dec.14, 2016, but the `068 patent is the subject of a patent term extension which will extend the term to March 8, 2018.  U.S. Patent No. 6,211,244 expires Oct. 23, 2015.

About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatic
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
2. Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System
3. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
4. Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Judes Patent Infringement Claims
5. Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
8. PDL BioPharma Receives Letter from Genentech Relating to European Patents
9. Olympus America Licenses Digital Pathology Patents to BioImagene, Inc.
10. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
11. ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... inflammatory disease and neurologic disorders, announced today the results ... citrate, the Company,s lead compound. Results from the study ... can significantly inhibit the activation of inflammatory proteins in ... this compound in a Phase 1 clinical trial under ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
(Date:6/30/2015)... Scotland , July 1, 2015 ... joins Nu C ana team   ... ProTide technology to develop and commercialise a portfolio of ... Chris McGuigan as Chief Scientific Officer. ... ProTide technology. He is currently Professor of Medicinal Chemistry ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3
... Amgen (Nasdaq: AMGN ), today announced the ... privately held biotechnology company based in Woburn, Mass., with ... a novel investigational oncolytic vaccine in Phase 3 clinical ... melanoma and head and neck cancer. The acquisition was ...
... , a leader in bioinformatics software and knowledge integration, ... license for Pathway Studio ® Enterprise system that ... MedScan® text processing technology for site-wide use. Pathway Studio ... pathways and develop mechanistic rationale for disease based on ...
Cached Medicine Technology:Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4Site-wide License for Ariadne's Pathway Studio Renewed by NCI 2
(Date:7/1/2015)... ... July 01, 2015 , ... METTLER TOLEDO is pleased to ... pans, ML-T balances give operators the room they need to carry out weighing ... makes ML-T balances a perfect choice for day-to-day weighing in nearly any analytical ...
(Date:7/1/2015)... ... July 01, 2015 , ... Northbound Treatment Services announced today ... Relations. , Emily originally entered the behavioral healthcare industry as an academic ... academic curriculum for clients to engage in their educational journey while in treatment. ...
(Date:7/1/2015)... City, UT (PRWEB) , ... July 01, 2015 ... ... compare the different philosophies and approaches to case management, placement, sober companionship and ... different training and approaches to working with and transporting clients with anxiety, ADHD, ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... southwest Georgia and the Florida Panhandle, the regional southeast Alabama community health ... messaging and clinical communications workflow solution provider. TelmedIQ, a burgeoning leader in ...
(Date:7/1/2015)... ... July 01, 2015 , ... Nutritional Products International, a brand focused ... products, recently attended the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in Tampa, ... The ECRM trade show allows companies the chance to meet with a ...
Breaking Medicine News(10 mins):Health News:METTLER TOLEDO Launches Compact ML-T Balances: Larger Pan Offers Greater Weighing Flexibility in Tight Spaces 2Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2Health News:Southeast Alabama Community Health System Chooses TelmedIQ to Meet Secure Text Messaging Challenges for Healthcare 2Health News:NPI Meets With Top Retail Figures at ECRM Conference 2
... under a ,Pay or Play, law, 10,entry-level employees will ... new study presented as,part of a Cornell University symposium ... provide health insurance to their employees or a pay,fine, ... the work,force., The study sponsored by the Employment ...
... success in helping children , FRIDAY, Nov. 9 (HealthDay ... juvenile rheumatoid arthritis, according to studies presented this week ... Boston. , One study found that abatacept, used to ... be a well-tolerated treatment for children and adolescents with ...
... 24 and Taclonex; Company ... financial guidance, ST. DAVID,S, Bermuda, Nov. 9 Warner Chilcott,Limited ... ended,September 30, 2007. Revenue in the quarter ended September 30, 2007 ... The,primary drivers of the increase in revenue were the net sales ...
... Del., Nov. 9 AstraZeneca (NYSE:,AZN) announced today ... has,approved CRESTOR(R) (rosuvastatin calcium) as an adjunct to ... with elevated cholesterol.,This new indication gives CRESTOR an ... "This new indication allows us to share what ...
... RURAL HALL, N.C., EXTON, Pa. and SAN DIEGO, ... a southeastern US,provider of oncology equipment sales and ... strategic alliance with Radiology Oncology Systems, Inc.,(ROS), an ... and Acceletronics, Inc., a US provider of oncology ...
... 8 State,Compensation Insurance Fund is presenting a ... Fund,s Employer Education Series, featuring its own,innovative and ... seminar entitled "Watch Your Back",introduces an educational and ... the very people they are trying to protect ...
Cached Medicine News:Health News:New Study: Health Insurance Mandates on Employers Hurt Low-Income Employees 2Health News:Drugs Can Ease Juvenile Rheumatoid Arthritis 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 2Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 3Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 4Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 2Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 3
... OmniMD Medical Billing system allows a ... accounting. It is integrated with the ... The system interfaces with electronic clearinghouses ... With a set of reports, it ...
... CPNG3 single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... CPNG3 reagent provides a long shelf ...
... Infinity Uric Acid single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Uric Acid reagent provides a ...
... Oxidase single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... Oxidase reagent provides a long shelf ...
Medicine Products: